Hematology

Latest News

First-line treatment for MDS often includes hypomethylating agents, so it is common for patients with sAML to have prior exposure to these agents. - Eleni - stock.adobe.com
Unmet Needs Remain in Secondary AML Following Treatment With HMAs

January 18th 2025

The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.

Man donating blood | Image Credit: © New Africa - stock.adobe.com
5 Medications That Defer Blood Donation

January 17th 2025

MRD status cannot be detected with a microscope and is achieved through bone marrow analysis | image credit: Arthur Constantine - stock.adobe.com
MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

January 13th 2025

Donating blood can save more than 1 life | image credit: Creative Cat Studio - stock.adobe.com
5 Things to Know About Donating Blood

January 10th 2025

mRNA vaccines can boost T cell responses | image credit: myskin - stock.adobe.com
Study Advocates Immunological Value of COVID-19 Vaccination in MM

January 9th 2025

More News

Transplant Eligibility, NCCN Recommendations, and Sequencing
December 19th 2019

Transplant Eligibility, NCCN Recommendations, and Sequencing

This Week in Managed Care: December 13, 2019
December 13th 2019

This Week in Managed Care: December 13, 2019

This week, the top managed care stories included the White House seeking a truce between CMS Administrator Seema Verma and HHS Secretary Alex Azar; Sanofi will shift its focus from diabetes to cancer drugs; results highlight real-world evidence of chimeric antigen receptor T-cell therapies.
Adding Daratumumab to Carfilzomib, Dexamethasone Improves PFS In Relapsed/Refractory Multiple Myeloma
December 10th 2019

Adding Daratumumab to Carfilzomib, Dexamethasone Improves PFS In Relapsed/Refractory Multiple Myeloma

Mary Caffrey
Although survival rates for multiple myeloma have improved as treatment options have increased, the disease remains incurable, and many patients stop current agents such as lenalidomide or bortezomib due to toxicity. Results of CANDOR involving a triple therapy were presented Tuesday at the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, Florida.
Apixaban Linked to Large Reductions in Major Bleeding, Recurrent VTE in Active Cancer
December 8th 2019

Apixaban Linked to Large Reductions in Major Bleeding, Recurrent VTE in Active Cancer

Maggie L. Shaw
Treating venous thromboembolism (VTE) in patients can be tricky due to greater risks of major bleeding episodes and recurrent VTE.
Fractures in Patients With MM Negatively Impact Survival, Study Says
December 6th 2019

Fractures in Patients With MM Negatively Impact Survival, Study Says

AJMC Staff
The findings show the importance of preventing bone disease in multiple myeloma (MM), the authors said.
FDA Approves Novel Sickle Cell Disease Treatment Voxelotor
November 26th 2019

FDA Approves Novel Sickle Cell Disease Treatment Voxelotor

Allison Inserro
The FDA Monday granted accelerated approval to voxelotor (Oxbryta) for the treatment of sickle cell disease in adults and pediatric patients 12 years or older.
Exercise Safe, Feasible in Older Patients With Newly Diagnosed Multiple Myeloma
November 26th 2019

Exercise Safe, Feasible in Older Patients With Newly Diagnosed Multiple Myeloma

Maggie L. Shaw
With their ongoing study, the authors also hope to show the physical effect of exercise on function, quality of life, pain, and bone disease.
New Inflammation Scoring System Aims to Add to ISS Staging
November 19th 2019

New Inflammation Scoring System Aims to Add to ISS Staging

Maggie L. Shaw
Tumor inflammatory response is significantly associated with poor prognosis in patients with multiple myeloma.
What We're Reading: Vape Flavor Ban Reversal; FDA Approves Sickle Cell Drug; FTC Clears BMS–Celgene Merger
November 18th 2019

What We're Reading: Vape Flavor Ban Reversal; FDA Approves Sickle Cell Drug; FTC Clears BMS–Celgene Merger

AJMC Staff
After saying he would back a ban on flavored vapes, President Trump now says he wants to study the issue more; the FDA approved Novartis’ crizanlizumab (Adakveo) as both monotherapy and in combination for patients 16 years or older with sickle cell disease; the Federal Trade Commission will allow Bristol-Myers Squibb to purchase Celgene for $74 billion in cash and stocks.
Site Logo
November 15th 2019

The Impact of Sickle Cell Disease on Lifetime Earnings

Allison Inserro
There are substantial reductions in income over a lifetime for patients with sickle cell disease owing to early mortality, according to a new study that seeks to provide a better understanding of the condition from both the patient point of view as well as a societal point of view.
Treatment-Free Remission at Heart of New CML Study
November 15th 2019

Treatment-Free Remission at Heart of New CML Study

Maggie L. Shaw
Researchers aim to eliminate leukemia stem cells safely.
Is Carfilzomib an Appropriate Treatment Option for Patients With Newly Diagnosed Multiple Myeloma?
November 13th 2019

Is Carfilzomib an Appropriate Treatment Option for Patients With Newly Diagnosed Multiple Myeloma?

Maggie L. Shaw
Updated Carthadex trial results show improved responses at the 58-month mark and build on findings from other studies.
Treating Facility, Provider Patient Volume and Sharing Influence Survival of MM Patients
November 9th 2019

Treating Facility, Provider Patient Volume and Sharing Influence Survival of MM Patients

Maggie L. Shaw
For their study, the authors wanted to expand on previous research results that suggest outcomes are improved among patients with multiple myeloma treated at high-volume facilities.
Blood Condition That Precedes Myeloma Presents Improved Chance for Early Treatment
November 7th 2019

Blood Condition That Precedes Myeloma Presents Improved Chance for Early Treatment

Allison Inserro
Monoclonal gammopathy of undetermined significance, a precancerous blood condition that rarely progresses to myeloma, can be predicted by a pattern of frequent hospital visits, and finding it earlier could present an opportunity to begin myeloma treatment earlier, thus improving outcomes.
CMS, CMMI Seek Feedback on Oncology Care First, Successor to OCM
November 3rd 2019

CMS, CMMI Seek Feedback on Oncology Care First, Successor to OCM

Mary Caffrey
There has been much speculation among the 175 practices still taking part in the OCM what will happen when the 5-year model expires in 2021. The RFI document states that the Oncology Care First model would start in January 2021, “when no new episodes would be initiating in OCM.”
Top 5 AJMC® Articles of October 2019
November 1st 2019

Top 5 AJMC® Articles of October 2019

Here are the top 5 articles for the month of October.
Quadruple Therapy for Newly Diagnosed Patients With MM Shows PFS Benefit Over Triple Therapy
October 29th 2019

Quadruple Therapy for Newly Diagnosed Patients With MM Shows PFS Benefit Over Triple Therapy

Allison Inserro
Quadruple therapy for newly diagnosed patients with multiple myeloma (MM) led to significantly longer progression-free survival (PFS), according to an abstract presented at the 17th International Myeloma Workshop 2019 in Boston, Massachusetts, last month.
Medicare Patients With Blood Cancer Face High Costs That May Impact Treatment
October 25th 2019

Medicare Patients With Blood Cancer Face High Costs That May Impact Treatment

Laura Joszt, MA
Less than half of Medicare patients newly diagnosed with blood cancer are receiving treatment for their cancer shortly after diagnosis, which may be attributed to the high cost burden they face, according to a new report from Milliman commissioned by The Leukemia & Lymphoma Society.
What Contributes to Delayed Engraftment After Autologous Hematopoietic Cell Transplantation?
October 24th 2019

What Contributes to Delayed Engraftment After Autologous Hematopoietic Cell Transplantation?

Allison Inserro
A recent study identified the pretransplant characteristics contributing to delayed engraftment (DE) following autologous hematopoietic cell transplantation (AHCT).
Blood Supply Falls Short of Need in Most Countries, Study Finds
October 18th 2019

Blood Supply Falls Short of Need in Most Countries, Study Finds

Mary Caffrey
The global blood shortage is unevenly distributed: Out of 195 countries examined in the study, 119 had unmet need totaling more than 102 million units, the equivalent of 1849 per 100,000 population worldwide.
Novel Drugs for MM Take Longer to Reach Black, Hispanic Patients Than White Patients
October 17th 2019

Novel Drugs for MM Take Longer to Reach Black, Hispanic Patients Than White Patients

Allison Inserro
The study found that, on average, it took nearly 2 months or longer for patients of color to receive immunomodulatory drugs such as lenalidomide and/or proteasome inhibitors such as bortezomib and carfilzomib. The use of these therapies has more than doubled survival of patients with multiple myeloma within the past decade.
Quality of Life Declines for Patients With Relapsed or Refractory MM Before Progression Appears
October 12th 2019

Quality of Life Declines for Patients With Relapsed or Refractory MM Before Progression Appears

Allison Inserro
Declines in global health status and quality of life, physical functioning, fatigue, and pain begin to appear 2 to 3 months before progression of the underlying malignant disease, multiple myeloma researchers said in a new study.
Study Connects Lymphoma Stage at Diagnosis to Risk of Secondary Cancer
October 10th 2019

Study Connects Lymphoma Stage at Diagnosis to Risk of Secondary Cancer

Mary Caffrey
The findings have implications for survivorship care, as more patients are living longer due to the availability of immunotherapies.
Ibrutinib Linked to Increased Hypertension Risk in Study
October 5th 2019

Ibrutinib Linked to Increased Hypertension Risk in Study

Mary Caffrey
Diagnosis of hypertension was based on guidelines updated by the American College of Cardiology and the American Heart Association in 2017.
Is Vacuolization Clinically Relevant When Examining Acute Myeloid Leukemia Blasts?
October 4th 2019

Is Vacuolization Clinically Relevant When Examining Acute Myeloid Leukemia Blasts?

AJMC Staff
A recent study said vacuolization can easily be determined and may be a useful biomarker to predict acute myeloid leukemia risk groups as well as early treatment response rates and survival.
FDA Grants Indication for Daratumumab Plus Combo in Newly Diagnosed Multiple Myeloma With Transplant
September 28th 2019

FDA Grants Indication for Daratumumab Plus Combo in Newly Diagnosed Multiple Myeloma With Transplant

AJMC Staff
The new indication is the seventh overall for the therapy, according to Janssen.
Researchers Say Second-Generation CAR T-Cell Therapy Proves Successful in Early Studies, Human Trial Planned
September 25th 2019

Researchers Say Second-Generation CAR T-Cell Therapy Proves Successful in Early Studies, Human Trial Planned

Allison Inserro
Researchers said Wednesday they created a second-generation chimeric antigen receptor (CAR) T-cell therapy that prevented relapse of lymphoma and leukemia and led to 100% long-term survival in early laboratory studies.
Celgene Announces Topline Results for Maintenance Therapy in Acute Myeloid Leukemia
September 18th 2019

Celgene Announces Topline Results for Maintenance Therapy in Acute Myeloid Leukemia

Mary Caffrey
Acute myeloid leukemia is the most common acute adult cancer diagnosed in the United States; 61,000 Americans are living with this disease and more than 10,000 will die of it this year.
Amgen Posts Updates on Triplet Therapy Using Carfilzomib
September 17th 2019

Amgen Posts Updates on Triplet Therapy Using Carfilzomib

AJMC Staff
Amgen recently announced early phase 3 CANDOR study data, showing the triple-drug combination of carfilzomib (Kyprolis), along with dexamethasone and daratumumab (Darzalex, sold by Janssen), met its primary end point of progression-free survival in patients with relapsed or refractory multiple myeloma, with a 37% reduction in the risk of progression or death.
Dr Ajai Chari Discusses the Importance of Real-World Evidence in Multiple Myeloma
September 11th 2019

Dr Ajai Chari Discusses the Importance of Real-World Evidence in Multiple Myeloma

Real-world outcomes are important because the populations included in clinical trials rarely reflect the populations actually being treated in the clinic, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.
<1
...
67891011121314
...
24>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo